• Home
  • Search Results

Research Studies

UNC-Chapel Hill Lineberger Comprehensive Cancer Center

Cancer - Lymphoma
36 studies match your search

Polatuzumab vedotin with R-GDP in relapsed/refractory diffuse large B-cell lymphoma

The purpose of this study is to look at the effectiveness of a combination of treatments, polatuzumab vedotin with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP) at treating relapsed or refractory diffuse large B-cell lymphoma.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Open

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Have you been recently diagnosed with Diffuse Large B Cell Lymphoma? Are you over 75 years of age? If so, you may be able to take part in a research study looking at the safety of giving a new study drug CC-486 (oral azacitidine) in addition to the standard chemotherapy drug combination used to treat this disease.

Age & Gender
  • 75 years ~ 99 years
  • Male, Female
Study Interest
  • Aging
  • Cancer (Lymphoma)
Not currently enrolling

Testing Early Treatment for Patients With High-Risk CLL or SLL

To evaluate whether early drug treatment extends overall survival compared with delayed drug treatment with high-risk (chronic lymphocytic leukemia [CLL] newly diagnosed asymptomatic CLL/SLL patients.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Leukemia, Lymphoma)
  • Chronic Conditions
  • Immune System/Infections
Open

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Have you been diagnosed with primary central nervous system (CNS) lymphoma? If so you may be able to take part in a research study looking at whether using the study drugs lenalidomide, and nivolumab can be safely used in addition to the standard treatment of primary CNS lymphoma, and which dose is the most adequate when they are used together.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)

Study of Acalabrutinib in Relapsed/Refractory CNS Lymphomas

The purpose of this study is to test whether giving the study drug acalabrutinib is safe and could help control B-cell Non-Hodgkin CNS lymphoma that have not gone away, or have come back, after the first round of treatment.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)

The HealthScore Health Coaching Program

The purpose of this research study is to deliver 6 months of 1:1 health coaching to cancer patients being treated at UNC Cancer Hospital. This program hopes to improve patient's self-confidence and satisfaction with how they feel and what they are able to do day-to-day. This includes exercising, support for healthy eating, emotional and social needs. Health coaching means you will receive weekly phone calls and emails from a trained coach.

Age & Gender
  • 15 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Behavior
  • Chronic Conditions
  • Mental and Emotional Health
  • and 4 more
Visit Location
100% Remote (online, phone, text)
Open

Phase II Study of CD30 CAR for relapsed/refractory CD30+ T Cell Lymphoma

Do you have Peripheral T Cell Lymphoma? Has your cancer come back or did it not get better with the last treatment you were given? If so, you may be eligible to participate in this gene therapy research study to learn more about using your own modified immune cells as possible treatment.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Open

CD19 CAR T-cells containing a Safety Switch to Treat Relapsed/Refractory B-cell Lymphoma

Have you been diagnosed with B-Cell Lymphoma? Are you looking for options to treat your cancer? If so, you may be able to take part in a research study looking at the safety of giving a new drug called iC9-CAR19 with Rimiducid.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Open

Study of CAR-T cells in relapsed/refractory Hodgkin's Lymphoma and Cutaneous T-Cell Lymphoma

Do you have Hodgkin's Lymphoma or Cutaneous T-Cell Lymphoma? Has your lymphoma come back, or has it not gotten better after your last treatment? If so, you might be able to take part in a study that will modify your own immune cells to see if it may treat your lymphoma.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Open

CD30 CAR-T cells for Hodgkin's/Non-Hodgkin's Lymphom

Do you have lymphoma that has come back, or did not get better with the last treatment you were given? If so, you might able to participate in a study to see if the study team can make modified T cells that are able to fight and kill the lymphoma cells.

Age & Gender
  • 3 years ~ 17 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Visit Location
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research